alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Company profile
Ticker
ALKS, ALKSV
Exchange
Website
CEO
Richard F. Pops
Employees
Location
Fiscal year end
Industry (SIC)
Former names
Antler Science Two Ltd, ANTLER SCIENCE TWO PLC
SEC CIK
Corporate docs
Subsidiaries
Alkermes Ireland Holdings Limited • Alkermes Pharma Ireland Limited • Daravita Pharma Ireland Limited • Alkermes Finance Ireland • Alkermes Science Four Limited • Alkermes Science Five Limited • Alkermes US Holdings, Inc. • Alkermes, Inc. • Alkermes Controlled Therapeutics, Inc. • Rodin Therapeutics, Inc. ...
IRS number
981007018
ALKS stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
1 May 24
8-K
Alkermes plc Reports First Quarter 2024 Financial Results
1 May 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
8-K
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
7 Mar 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Results of Operations and Financial Condition
15 Feb 24
Transcripts
ALKS
Earnings call transcript
2024 Q1
1 May 24
ALKS
Earnings call transcript
2023 Q4
15 Feb 24
ALKS
Earnings call transcript
2023 Q3
25 Oct 23
ALKS
Earnings call transcript
2023 Q2
26 Jul 23
ALKS
Earnings call transcript
2023 Q2
26 Jul 23
ALKS
Earnings call transcript
2023 Q1
26 Apr 23
ALKS
Earnings call transcript
2022 Q4
16 Feb 23
ALKS
Earnings call transcript
2022 Q3
2 Nov 22
ALKS
Earnings call transcript
2022 Q2
27 Jul 22
ALKS
Earnings call transcript
2022 Q1
27 Apr 22
Latest ownership filings
4
Nancy Lurker
12 Apr 24
144
Notice of proposed sale of securities
18 Mar 24
4
Christian Todd Nichols
18 Mar 24
3
Nancy Lurker
15 Mar 24
4
Christian Todd Nichols
27 Feb 24
4
Samuel Joseph Parisi
27 Feb 24
4
Iain Michael Brown
27 Feb 24
4
David Joseph Gaffin
27 Feb 24
4
MICHAEL J LANDINE
27 Feb 24
4
Blair Curtis Jackson
27 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 647.71 mm | 647.71 mm | 647.71 mm | 647.71 mm | 647.71 mm | 647.71 mm |
Cash burn (monthly) | 6.03 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 44.43 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 603.28 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 100.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
0.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 11 |
Closed positions | 274 |
Increased positions | 11 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 29.83 bn |
Total shares | 1.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Allspring Global Investments | 377.49 k | $10.47 bn |
Mutual Of America Capital Management | 119.98 k | $3.33 bn |
Redwood Investments | 115.98 k | $3.22 bn |
State of Alaska, Department of Revenue | 102.67 k | $2.85 mm |
Mirae Asset Global Investments | 91.33 k | $2.53 bn |
Nisa Investment Advisors | 88.77 k | $2.46 bn |
Assenagon Asset Management | 73.17 k | $2.03 bn |
DekaBank Deutsche Girozentrale | 54.98 k | $1.51 mm |
Moody Aldrich Partners | 52.57 k | $1.46 bn |
New York State Teachers Retirement System | 49.40 k | $1.37 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Nancy Lurker | Non Qualified Stock Option Ordinary Shares | Grant | Acquire A | No | No | 24.99 | 22,103 | 552.35 k | 22,103 |
11 Apr 24 | Nancy Lurker | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 11,255 | 0.00 | 11,255 |
11 Apr 24 | Nancy Lurker | Non Qualified Stock Option Ordinary Shares | Grant | Acquire A | No | No | 24.99 | 4,833 | 120.78 k | 4,833 |
11 Apr 24 | Nancy Lurker | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 2,323 | 0.00 | 2,323 |
18 Mar 24 | Christian Todd Nichols | Ordinary Shares | Sell | Dispose S | No | Yes | 28.1021 | 10,417 | 292.74 k | 65,911 |
26 Feb 24 | Richard F Pops | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 30.04 | 274,328 | 8.24 mm | 274,328 |
26 Feb 24 | Christian Todd Nichols | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 21,638 | 0.00 | 21,638 |
26 Feb 24 | Christian Todd Nichols | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 30.04 | 87,602 | 2.63 mm | 87,602 |
23 Feb 24 | Christian Todd Nichols | Ordinary Shares | Payment of exercise | Dispose F | No | No | 29.57 | 2,845 | 84.13 k | 76,328 |
23 Feb 24 | Christian Todd Nichols | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 6,407 | 0.00 | 79,173 |
News
7 Analysts Assess Alkermes: What You Need To Know
2 May 24
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
2 May 24
Alkermes Q1 2024 Adj EPS From Continuing Operations $0.44 Misses $0.58 Estimate
1 May 24
Alkermes Q1 Sales $350.372M Miss $360.258M Estimate
1 May 24
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
9 Apr 24
Press releases
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
2 May 24
Alkermes plc Reports First Quarter 2024 Financial Results
1 May 24
Alkermes to Report First Quarter Financial Results on May 1, 2024
17 Apr 24
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
9 Apr 24
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
8 Apr 24